Anteris Technologies Global Corp Dossier
Qualitative Analysis
Business overview
Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) is a clinical-stage structural heart medical device company focused on designing, developing, and commercializing innovative solutions to treat heart valve diseases. The company's flagship product is the DurAVR Transcatheter Heart Valve (THV) System, a novel, biomimetic, balloon-expandable heart valve designed to treat severe aortic stenosis. Unlike traditional three-piece prosthetic valves, the DurAVR THV is constructed from a single piece of molded ADAPT bovine tissue, which is engineered using the company's proprietary anti-calcification technology to mimic the performance and laminar flow of a healthy human aortic valve. Anteris also develops the ComASUR delivery system, a steerable catheter designed for precise anatomical alignment during valve deployment.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
A prospective, randomized controlled trial evaluating the safety and clinical effectiveness of the DurAVR Transcatheter Heart Valve (THV) compared to commercially available TAVR systems. The trial is designed to enroll approximately 1,000 patients in an 'All Comers Randomized Cohort' with 1:1 randomization.
Expected impact: Aims to demonstrate non-inferiority on a primary composite endpoint of all-cause mortality, stroke, and cardiovascular hospitalization at one year, establishing a pathway to FDA and CE Mark approvals.
Scaling up manufacturing capabilities and operational infrastructure to support clinical activities and future commercialization. This includes the execution of an 11-year lease for a new 181,436 square foot facility in Brooklyn Park, Minnesota, starting September 1, 2026.
Expected impact: Provides a secure, long-term operational base to scale up production capacity, improve logistics, and enhance R&D capabilities for the DurAVR THV System.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Deepens strategic alignment with a major global player in the structural heart industry. Medtronic's subsidiary (Covidien Group S.à r.l.) secured registration and investor rights, a non-voting board observer seat, and a structured right to negotiate on certain future acquisition proposals.
Terms: Medtronic made a strategic private placement investment of up to $90 million as part of Anteris's aggregate $320 million capital raises completed in January 2026.
Anteris elected to discontinue additional development contributions under their 2023 agreement to strategically refocus capital and resources on its core DurAVR aortic valve platform. This terminates the active co-development of the VClip mitral/tricuspid repair system.
Terms: Anteris paid a break fee of $400,000 to v2vmedtech on April 28, 2026, ending further funding obligations and triggering options for v2v's initial shareholders to either buy out Anteris's stake or dilute it to a capped minority position.